Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates

Incyte Corporation (INCY) reported fourth-quarter 2023 adjusted earnings of $1.06 per share, which missed the Zacks Consensus Estimate of $1.21. The company had recorded earnings of 62 cents per share in the year-ago quarter.Total revenues in the reported quarter were $1.01 billion, which grew 9.3% year over year, driven by the sustained performance of the lead drug, Jakafi (ruxolitinib), and increased sales of Opzelura (ruxolitinib) on strong launch and demand. The top line, however, marginally missed the ...